Register for our free email digests:
Latest From Merz Pharma Group
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.
New Enterprise Associates registered one of its biggest returns ever when Merz agreed to pay up to $600 million for aesthetics company Ulthera. CEO Matthew Likens and lead investor Justin Klein, MD, discuss specifics about the blockbuster deal.
Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- SpineGuard SA
- Senior Management
Pierre Jerome, CEO
Manuel Lanfossi, CFO
Stéphane Bette, CTO
- Contact Info
Phone: (33) 1 45 18 45 19
10, Cours Louis Lumière
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.